Application of 3 mg/kg of cyclosporine a (NEORAL®) once daily is effective for severe and moderate psoriasis

Nishinihon Journal of Dermatology

Volumn 71, Issue 1, 2009, Pages 63-69

  Takahashi, Hidetoshi ^a   Tsuji, Hitomi ^a   Iizuka, Hajime ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; HUMAN; PATIENT SATISFACTION; PSORIASIS VULGARIS; QUALITY OF LIFE; QUESTIONNAIRE; SKIN DEFECT; SKIN MANIFESTATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 62349125548     PISSN: 03869784     EISSN: None     Source Type: Journal    
DOI: 10.2336/nishinihonhifu.71.63     Document Type: Article

References (15)

1. Nakayama J et al: Comparison of two therapeutic regimens, continuous monotherapy and intermittent therapy, for long-term maintenance of remission of psoriasis with cyclosporine A. Eur J Dermatol 6: 341-343, 1996.
2. Japanese source
3. Japanese source
4. Japanese source
5. Japanese source
6. Japanese source
7. Japanese source
8. Japanese source
9. Japanese source
10. Rapp SR et al: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41: 401-407, 1999.
11. Finlay AY et al: Psoriasis: an index of disability. Clin Exp Dermatol 120: 8-11, 1987.
12. Japanese source
13. Japanese source
14. Japanese source
15. Japanese source